The Bone Cancer Research Trust is proud to unveil its latest impact report, Striving for Progress Through Research, which outlines the progress that has been made towards improving patient outcomes.
While the effects of the Covid-19 pandemic and cost of living crisis continue to be felt by the primary bone cancer community, we remain more committed than ever to facilitating collaborative research that is aimed at accelerating the discovery of newer, kinder treatments for our patients.
Since our last impact report in 2021, and with the support of the incredible bone cancer community, we are proud to share that we have:
- Doubled our research investment, committing £4 million to research over the last two years and taking our total to over £8 million.
- Facilitated the collection of 12,438 patient samples through our Infrastructure Grants.
- Completed our first clinical study, ICONIC, with Ad-ICONIC continuing as the largest osteosarcoma collaboration in the UK.
- Awarded our first Clinical Trial Support Grant to introduce Lenvatinib to the rEECur trial for Ewing sarcoma patients.
- Provided 45 research grants to support early career researchers, representing 32% of our total investment.
- Lead to the creation of 111 scientific publications as a direct result of the research we have funded, which has been cited in scientific literature 3910 times.
Dr Zoe Davison, Head of Research, Information & Support at the Bone Cancer Research Trust, said:
I'm delighted to share our latest Research Impact Report, which demonstrates the measurable difference we have made for bone cancer patients despite the tough economic conditions we have all found ourselves in. It is only with the unwavering support of our incredible community, who continue to raise vital funds with their tireless efforts, that this has been made possible. Whilst this is an incredible achievement, there is much more that needs to be done to give all patients the best chance to survive primary bone cancer. This is why we need your continued support now more than ever.
To read our latest Research Impact Report in full, click below: